VDRM Stock Overview
ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ViaDerma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0095 |
| 52 Week High | US$0.018 |
| 52 Week Low | US$0.008 |
| Beta | 0 |
| 1 Month Change | 6.44% |
| 3 Month Change | -8.61% |
| 1 Year Change | -36.63% |
| 3 Year Change | -40.59% |
| 5 Year Change | 459.12% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| VDRM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.0% | -2.3% | -3.7% |
| 1Y | -36.6% | 11.4% | 20.2% |
Return vs Industry: VDRM underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: VDRM underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| VDRM volatility | |
|---|---|
| VDRM Average Weekly Movement | 20.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VDRM's share price has been volatile over the past 3 months.
Volatility Over Time: VDRM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Christopher Otiko | viadermalicensing.com |
ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company’s lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.
ViaDerma, Inc. Fundamentals Summary
| VDRM fundamental statistics | |
|---|---|
| Market cap | US$11.73m |
| Earnings (TTM) | -US$1.52m |
| Revenue (TTM) | US$44.69k |
0.0x
P/S Ratio0.0x
P/E RatioIs VDRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VDRM income statement (TTM) | |
|---|---|
| Revenue | US$44.69k |
| Cost of Revenue | US$7.06k |
| Gross Profit | US$37.63k |
| Other Expenses | US$1.56m |
| Earnings | -US$1.52m |
Last Reported Earnings
Dec 31, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did VDRM perform over the long term?
See historical performance and comparison